Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.
Approval Alert | Afamitresgene Autoleucel in Unresectable Synovial Sarcoma
Accelerated approval of afami-cel may expand access to therapy for patients who are unable to live near certain treatment centers.
Treatment with afami-cel may offer improved quality of life to patients with metastatic synovial sarcoma compared with continuous chemotherapy.
The SeCore CDx HLA A Sequencing System may help identify patients with advanced synovial sarcoma who are suitable to receive afami-cel.
Data from SPEARHEAD-1 support the accelerated approval of afamitresgene autoleucel in metastatic or unresectable synovial sarcoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC
2
EMD Associated With Poorer Outcomes in Previously Treated R/R Multiple Myeloma
3
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
4
Pre-Cevostamab Treatment May Not Impact Outcomes as Much in Multiple Myeloma
5
